All articles by Abi Millar
Abi Millar
Youth mental health: can digital tools contain the crisis?
Mental health services are under an unprecedented strain. Virtual therapy sessions and mental health apps are emerging to fill the gap.
Robotic-powered prostheses – state of play
Mind-controlled bionic limbs no longer sound so far-fetched. What will it take to bring them to the patients who need them?
Microneedle tech: 3D printing to the rescue
Will next-generation manufacturing tech propel the viability of microneedle patches as advantageous drug delivery systems?
Are metaverse applications becoming a reality in medical training?
The realisation of an immersive virtual world for medical training relies on the maturity of AR and VR technologies.
The future of ALS devices: next gen assistive technology aims to give patients a voice
Brain-computer interfaces, IoT and AI to fuel the advancement of assistive technology devices for ALS patients.
How to make lateral flow tests more sustainable?
Self-testing has become a regular part of life, thanks to the pandemic. But what does the boom in lateral flow tests mean for the environment, and what can medical device companies do about all that single-use plastic?
Taming the Wild West: regulating digital health apps
Health-related smartphone apps have surged in number and popularity, especially during the pandemic, but they are sparsely monitored. We ask if the sector is in need of regulatory reform.
Medical devices for rare diseases: the unmet need
Patients with rare diseases often lack medical devices suitable for their condition, a problem which a new working group from the International Rare Disease Research Consortium aims to address.
Point-of-Care diagnostics: a boon awaits under remote healthcare
As remote healthcare gathers traction, patients with chronic diseases could get easier access to diagnostic data than ever before.
Patient advisors: could they change the face of medtech trials?
The FDA has released new guidance on how to integrate patient engagement in medical device clinical studies. How might patient advisors add value to these trials?